A Multiple Ascending Dose Study of MEDI7247 in Participants with Selected Relapsed/Refractory Hematological Malignancies

Trial Identifier: D8540C00001
Sponsor: MedImmune, LLC
NCTID:: NCT03106428
Start Date: March 2017
Primary Completion Date: January 2020
Study Completion Date: January 2020
Condition: Leukemia; Lymphoma; Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
French translation
Korean translation

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 1Z5
France Pierre Benite, France, 69495
France Villejuif, France, 94805
South Korea Seoul, South Korea, 06351
South Korea Seoul, South Korea, 03080
United States of America, AR Little Rock, AR, United States of America, 72205
United States of America, CA Los Angeles, CA, United States of America, 90095
United States of America, CO Denver, CO, United States of America, 80218
United States of America, FL Tampa, FL, United States of America, 33612
United States of America, GA Atlanta, GA, United States of America, 30322
United States of America, IL Chicago, IL, United States of America, 60611
United States of America, MA Boston, MA, United States of America, 02114
United States of America, MO St. Louis, MO, United States of America, 63110
United States of America, NY New York, NY, United States of America, 10065
United States of America, SC Greer, SC, United States of America, 29650
United States of America, TN Nashville, TN, United States of America, 37203
United States of America, TX Houston, TX, United States of America, 77030
United States of America, TX San Antonio, TX, United States of America, 78229
United States of America, WA Seattle, WA, United States of America, 98109